Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran; Connective Tissue Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Liver and Gastrointestinal Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Complement Ther Med. 2020 Mar;49:102351. doi: 10.1016/j.ctim.2020.102351. Epub 2020 Feb 19.
Current study aimed to find the effects of curcumin on quality of life (QoL) in liver cirrhotic patients.
In this randomized double-masked placebo-controlled trial, 70 cases with liver cirrhosis aged 20-70 years were randomly divided into two groups to receive 1000 mg/day curcumin (n = 35) or placebo (n = 35) for 12 weeks. The health-related QoL (HRQoL) was assessed by CLDQ, LDSI 2.0, and SF-36.
Fifty-eight patients (28 in curcumin and 30 in placebo groups) finished the research. Compared with baseline, overall scores as well as most of CLDQ domains (e.g. Fatigue, Emotional Function, Worry, Abdominal Symptoms, and Systemic Symptoms) and the Physical and Mental health (Total) scores and most of SF-36 domains (e.g. Physical Functioning, Bodily Pain, Vitality, Social Functioning, and Mental Health) increased considerably (P < 0.05) after curcumin administration. Furthermore, curcumin reduced most of LDSI 2.0 domains (e.g. Itch, Joint pain, Pain in the right upper abdomen, Sleeping during the day, Decreased appetite, Depression, Fear of complication, Jaundice, Hindrance in Financial Affairs, Change in use of time, Decreased sexual interest, and Decreased sexual activity) significantly (P < 0.05). Significant differences were noticed between two groups in CLDQ domains and overall scores, LDSI 2.0 domains and overall scores, SF-36 Physical and Mental health (total) scores and all its domains scores (P < 0.05), adjusting for baseline values and disease duration.
Curcumin improved QoL in liver cirrhotic patients according to CLDQ, LDSI 2.0, and SF-36 domains. Additional studies are warranted to consider curcumin as a safe, accessible, and low-cost complementary therapeutic option in cirrhosis.
本研究旨在探讨姜黄素对肝硬化患者生活质量（QoL）的影响。
这是一项随机、双盲、安慰剂对照试验，纳入 70 例年龄在 20-70 岁的肝硬化患者，随机分为两组，分别接受 1000mg/天姜黄素（n=35）或安慰剂（n=35）治疗 12 周。采用 CLDQ、LDSI 2.0 和 SF-36 评估健康相关 QoL（HRQoL）。
58 例患者（姜黄素组 28 例，安慰剂组 30 例）完成了研究。与基线相比，姜黄素治疗后 CLDQ 总分及疲劳、情绪功能、担忧、腹部症状和全身症状等多个领域，SF-36 总分及生理功能、躯体疼痛、活力、社会功能和心理健康等多个领域评分显著升高（P<0.05）。此外，姜黄素还显著降低了 LDSI 2.0 中瘙痒、关节痛、右上腹痛、白天嗜睡、食欲下降、抑郁、担心并发症、黄疸、经济困难、时间安排改变、性欲下降和性生活减少等多个领域评分（P<0.05）。两组间 CLDQ 各领域和总分、LDSI 2.0 各领域和总分、SF-36 生理和心理健康（总分）及其各领域评分差异均有统计学意义（P<0.05），校正基线值和疾病持续时间后差异仍有统计学意义。
姜黄素可通过 CLDQ、LDSI 2.0 和 SF-36 多领域改善肝硬化患者的生活质量。需要进一步研究以确定姜黄素是否可作为一种安全、易得、低成本的肝硬化补充治疗选择。
